Researchers mapped antibody targets across solid tumors
- Researchers mapped antibody targets across solid tumors
- An anti-FOLR1 antibody-drug conjugate boosts immunotherapy in bowel cancer
- Lung cancer study finds broad testing but limited gene profiling in Malaysia
- Isolation and distress linked to higher death risk in cancer patients
- Human papillomavirus testing found more cervical precancers in women with HIV
Researchers mapped antibody targets across solid tumors
Researchers analyzed more than 32,000 specimens across solid tumors and mapped 87 antibody targets. Their tools matched tumor profiles to antibody trials and predicted responses in patient-derived models.
“We develop an AI-based decision-support agent for antibody trial matching and construct a multimodal feature space integrating tumor- and protein-intrinsic attributes to guide systematic target discovery and prioritization.”
Why it matters. People with solid tumors may be matched to antibody trials based on the features of their cancer. It studied patient records rather than testing a treatment.
Cancer Discovery, 18 Nov 2026 · Human observational studyAn anti-FOLR1 antibody-drug conjugate boosts immunotherapy in bowel cancer
Researchers studied bowel cancer cells and patient samples, then tested an anti-FOLR1 antibody-drug conjugate with anti-PD-1 therapy in vivo. The combination caused tumor regression.
“Our findings support anti-FOLR1 antibody-drug conjugate (an antibody that delivers chemotherapy straight to cancer cells) as a clinically actionable approach to overcome immune evasion and unlock immunotherapy (treatment that helps the immune system fight cancer) effectiveness in colorectal cancer.”
Why it matters. Lab or animal research on bowel cancer. Not yet tested as a treatment in people; many lab results never reach patients.
Science Translational Medicine, 18 Nov 2026 · Translational research (lab work plus patient samples)Lung cancer study finds broad testing but limited gene profiling in Malaysia
Researchers reviewed records for 577 people with lung cancer in Sarawak, Malaysia. While 86.7% had molecular testing, only 8.5% had more complete gene testing.
“Reliance on limited assays risks underdetection of actionable genomic alterations and perpetuates inequities in access to targeted therapies and clinical trials.”
Why it matters. People with lung cancer in Malaysia could benefit from more complete gene testing to find treatment options. It studied patient records rather than testing a treatment.
JCO Global Oncology, 18 Nov 2026 · Human observational studyIsolation and distress linked to higher death risk in cancer patients
Researchers studied 45,651 people with cancer. Lack of regular social contact, living alone, depression and anxiety were each linked to a higher risk of death.
“Because these domains can be captured with brief self-report items within psychosocial screening, which is increasingly standard in oncology, social isolation screening represents a low-burden addition to risk stratification and supportive care prioritization.”
Why it matters. Screening could help care teams identify people with cancer who may need more support for isolation or distress. It studied patient records rather than testing a treatment.
JCO Oncology Practice, 18 Nov 2026 · Human observational study | 45,651 patientsHuman papillomavirus testing found more cervical precancers in women with HIV
Among 575 women living with HIV in the Dominican Republic, self-collected human papillomavirus tests found 97.0% of severe cervical precancers. This was more than provider-collected tests or cervical cell checks.
“These findings support transitioning to primary HPV-based screening for WWH in the Dominican Republic to increase accuracy in detecting precancer and reduce the cervical cancer burden among WWH.”
Why it matters. Women living with HIV may benefit from more accurate cervical cancer screening that uses samples they collect themselves. It studied patient records rather than testing a treatment.
JCO Global Oncology, 18 Nov 2026 · Human observational studyDeals and stopped trials
- SSGJ-707 in Advanced Non-Small Cell Lung CancerTerminated · Phase III · Shenyang Sunshine Pharmaceutical Co., LTD. · Reason given: Sponsor decided
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid TumorsTerminated · Phase I · Changchun GeneScience Pharmaceutical Co., Ltd. · Reason given: The sponsor adjusted its research and development strategy
India
- AI and the future of pharmacy educationexpresspharma.in
Worth watching
- Study maps antibody targets across several types of cancerResearchers analyzed more than 32,000 tumor samples across solid cancers. They built tools to rank antibody targets and match patients to trials.
- An antibody-drug conjugate boosted immunotherapy in bowel cancer modelsResearchers studied bowel cancer cells and patient samples. In tests, the antibody-drug conjugate mirvetuximab soravtansine combined with anti-PD-1 therapy boosted antitumor activity and caused tumors to shrink.
- Lung cancer testing in Malaysia often used narrow gene testsResearchers reviewed records for 577 people with lung cancer in Sarawak, Malaysia. Although 86.7% had molecular testing, only 8.5% received broad genetic testing.
- Accelerating access to precision oncology trials: risk-benefit framework for local biomarker tests for patient enrollmentResearch finding, npj Precision Oncology, 18 Nov 2026
- Fatal Capecitabine Toxicity Despite Negative Standard DPYD Screening in a Patient With Breast Cancer Harboring Hypomorphic Variants: A Case ReportResearch finding, JCO Precision Oncology, 18 Nov 2026
- Alterations in homologous recombination repair genes and impact on survival among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencingResearch finding, Scientific Reports, 18 Nov 2026